---
schema_version: "secwatch.filing_event.v1"
accession: "0000014272-22-000164"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:05:44.237276+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bristol-Myers Q2 revenue $11.9B (+2% YoY); Non-GAAP EPS $1.93 (+18%); GAAP EPS guidance adjusted

## Summary
- Q2 revenue $11.887B, up 2% (5% ex-FX); U.S. revenue +12% to $8.3B, international revenue -16% (-8% ex-FX).
- GAAP EPS $0.66 (up 40%); non-GAAP EPS $1.93 (up 18%); GAAP net earnings $1.4B vs $1.1B.
- In-line product revenue +11% YoY (Eliquis +16%, Opdivo +8%); Revlimid -22% on generic erosion.
- New product portfolio added $257M (Abecma, Opdualag, Reblozyl); Acquired IPRD charges $400M.
- 2022 GAAP EPS guidance adjusted; non-GAAP EPS guidance reaffirmed; dividend maintained at $0.54/share.

## SEC filing metadata
- accession: 0000014272-22-000164
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000001427222000164/0000014272-22-000164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000001427222000164/bmy-20220727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000014272-22-000164
- JSON: https://secwatch.observer/filing/0000014272-22-000164.json
- Plain text: https://secwatch.observer/filing/0000014272-22-000164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.